

GLP-1s: The Heart's Newest Best Friend (Broadcast)

INTRO:

IT'S BEEN TWO DECADES SINCE THE FIRST-EVER GLP-1 MEDICATION WAS APPROVED BY THE F-D-A.

FOR YEARS GLP-1S HAVE BEEN USED TO HELP THOSE WITH DIABETES. MORE RECENTLY – GLP-1 PRODUCERS HAVE BEGUN MARKETING DRUGS LIKE OZEMPIC® ... WEGOVY® ... ZEPBOUND® OR MOUNJARO® FOR WEIGHT LOSS.

NOW HEALTH EXPERTS BELIEVE THESE MEDICATIONS CAN PROVIDE A ROBUST BENEFIT TO HEART HEALTH.

TAKE VO

THIS COMES AS THE AMERICAN COLLEGE OF CARDIOLOGY RELEASED ITS FIVE TOP TRENDS IN CARDIOVASCULAR MEDICINE IN 2025... INCLUDING "ANTI-OBESITY DRUGS: CARDIOVASCULAR BENEFIT BEYOND WEIGHT LOSS."

THE A-C-C REPORTS THAT CLINICAL TRIALS SHOW THESE MEDICATIONS CAN REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS BY UP TO 20-PERCENT IN PATIENTS WITH OBESITY AND PREEXISTING CARDIOVASCULAR CONDITIONS. DR. CHRISTOPHER SPARROW – AN ADVANCED HEART FAILURE CARDIOLOGIST WITH OSF HEALTHCARE – SAYS HE'S SEEN SOME REMARKABLE BENEFITS IN MANY OF HIS PATIENTS.

TAKE SOT | DR. CHRISTOPHER SPARROW | ADVANCED HEART FAILURE CARDIOLOGIST | OSF HEALTHCARE

"The biggest thing I've seen in my practice is that patients who are obese can take these medications and have dramatic reductions in their weight, while doing it in a healthy fashion with a tolerable treatment. When these patients lose weight, they feel better, their blood pressure gets better, their cholesterol gets better, and their diabetes get better if they have it. If they don't have it, their risk of getting diabetes goes down. Plus, their quality of life improves."

VO TAG

DR. SPARROW SAYS RECENT EVIDENCE SHOWS THAT IN THE OBESE POPULATION WITH HEART FAILURE – THESE DRUGS IMPROVE QUALITY OF LIFE AND THE ABILITY FOR THE PEOPLE TO FUNCTION BETTER. WHEN IT COMES TO OBESITY – MEDICARE RECENTLY ANNOUNCED IT WOULD COVER THESE DRUGS FOR OBESE PATIENTS WITH CARDIOVASCULAR DISEASE. IT'S ESTIMATED THIS COULD IMPACT ROUGHLY THREE-POINT-FOUR MILLION AMERICANS.